중추신경계(CNS) 치료제 Drug Discovery용 인공지능(AI) 시장 : 전략적 인사이트와 예측(2026-2035년)

The Global AI in CNS Drug Discovery Market is projected to grow at a CAGR of 15.8% the forecast period, increasing from USD 311.05 million in 2026 to USD 1,168.94 million by 2035.

The application of artificial intelligence (AI) in CNS drug discovery is transforming one of the most complex and challenging areas of pharmaceutical research. Central nervous system disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, epilepsy, schizophrenia, depression, and other neurodegenerative and psychiatric conditions, continue to pose significant clinical and commercial challenges due to complex disease biology, limited understanding of underlying mechanisms, and historically high drug development failure rates.

Traditional CNS drug discovery processes often require extensive time, significant financial investment, and prolonged clinical evaluation. AI technologies are increasingly being deployed to improve target identification, biomarker discovery, compound screening, patient stratification, predictive modeling, and clinical trial optimization. By leveraging machine learning, deep learning, natural language processing, and advanced data analytics, pharmaceutical companies can analyze vast datasets more efficiently and identify promising therapeutic candidates with greater precision. As the demand for innovative neurological therapies continues to rise, AI is expected to become a critical enabler of future CNS drug development.

Market Drivers

Rising Prevalence of CNS Disorders

One of the primary drivers of the market is the growing global burden of neurological and psychiatric disorders. Aging populations, increasing life expectancy, and rising awareness of mental health conditions are contributing to higher disease prevalence worldwide.

The increasing incidence of Alzheimer's disease, Parkinson's disease, depression, schizophrenia, epilepsy, and other CNS disorders is creating urgent demand for innovative therapeutic solutions. AI-powered drug discovery platforms offer the potential to accelerate the identification of novel treatment candidates and address substantial unmet medical needs.

Need to Improve Drug Discovery Efficiency

CNS drug development has historically experienced lower success rates compared to many other therapeutic areas. The complexity of brain biology, limited predictive models, and challenges associated with crossing the blood-brain barrier have contributed to high research and development costs.

Artificial intelligence technologies help researchers analyze complex biological datasets, identify hidden relationships, and improve candidate selection, potentially reducing development timelines and increasing the probability of success.

Growing Adoption of AI Across the Pharmaceutical Industry

Pharmaceutical and biotechnology companies are increasingly integrating AI solutions into research workflows to enhance productivity and innovation. AI platforms can support target discovery, molecular design, toxicity prediction, drug repurposing, and clinical trial optimization.

The growing acceptance of AI-driven research methodologies is accelerating investment in specialized CNS drug discovery platforms and expanding market opportunities.

Increasing Availability of Biomedical Data

The proliferation of genomic databases, neuroimaging repositories, electronic health records, clinical trial datasets, and real-world evidence platforms is creating a rich foundation for AI-driven research.

Advanced algorithms can process large volumes of structured and unstructured data to generate insights that would be difficult to identify through conventional research methods. This growing data ecosystem is significantly supporting market expansion.

Market Restraints

Data Quality and Integration Challenges

Although large volumes of healthcare and research data are available, significant variability exists in data quality, standardization, and accessibility. Integrating heterogeneous datasets from multiple sources remains a major challenge for AI-based drug discovery programs.

Incomplete or biased datasets may affect algorithm performance and reduce predictive accuracy.

Regulatory and Validation Uncertainty

The use of artificial intelligence in pharmaceutical development is still evolving, and regulatory frameworks governing AI-assisted research continue to develop. Demonstrating the reliability, transparency, and reproducibility of AI-generated insights remains an important consideration.

Regulatory uncertainty may influence adoption rates and affect commercialization strategies for AI-powered drug discovery solutions.

High Implementation Costs

Developing and deploying advanced AI platforms requires significant investments in computational infrastructure, specialized talent, software development, and data acquisition. Smaller biotechnology firms and research organizations may face challenges in adopting sophisticated AI technologies due to budget constraints.

The shortage of professionals with expertise in both artificial intelligence and neuroscience can further limit implementation efforts.

Technology and Segment Insights

The global AI in CNS drug discovery market can be segmented by technology, application, therapeutic area, end user, and geography.

By technology, the market includes machine learning, deep learning, natural language processing, computer vision, predictive analytics, neural networks, and advanced data mining platforms. Machine learning and deep learning technologies account for a significant share due to their ability to identify patterns within complex biological and clinical datasets.

By application, the market includes target identification and validation, biomarker discovery, compound screening, lead optimization, drug repurposing, toxicity prediction, clinical trial design, and patient stratification. Target identification and drug repurposing are emerging as particularly important applications because AI can rapidly evaluate biological pathways and existing drug databases to identify new therapeutic opportunities.

By therapeutic area, the market encompasses neurodegenerative disorders, psychiatric disorders, neurodevelopmental disorders, epilepsy, multiple sclerosis, chronic pain conditions, and other CNS diseases. Neurodegenerative diseases represent a major segment due to increasing prevalence and substantial unmet treatment needs. Psychiatric disorders also represent a significant area of research activity as scientists seek biologically targeted treatment approaches.

By end user, the market includes pharmaceutical companies, biotechnology firms, contract research organizations, academic institutions, research centers, and healthcare organizations. Pharmaceutical and biotechnology companies account for a major share due to their extensive investments in drug discovery and development programs. Academic institutions continue to play an important role in algorithm development, biomarker discovery, and translational neuroscience research.

Technological advancements are continuously expanding the capabilities of AI-driven CNS research. Integration of multi-omics analysis, digital biomarkers, cloud computing, generative AI models, federated learning systems, and advanced simulation platforms is improving research efficiency and accelerating therapeutic discovery. AI-enabled digital twins and predictive disease modeling are also emerging as promising tools for evaluating treatment responses and optimizing clinical development strategies.

Geographically, North America dominates the market due to strong pharmaceutical research infrastructure, substantial artificial intelligence investments, advanced healthcare systems, and a high concentration of biotechnology companies. Europe maintains a significant market presence supported by neuroscience research initiatives and increasing adoption of digital health technologies. Asia-Pacific is expected to witness the fastest growth owing to expanding biotechnology sectors, increasing healthcare investments, growing AI capabilities, and rising neurological disease burden. Latin America and the Middle East & Africa are gradually increasing participation through healthcare modernization and research collaborations.

Competitive and Strategic Outlook

The AI in CNS drug discovery market is characterized by growing collaboration among pharmaceutical companies, biotechnology firms, artificial intelligence developers, cloud computing providers, academic institutions, and research organizations. Strategic partnerships are becoming increasingly important as organizations seek to combine expertise in neuroscience, computational biology, and machine learning.

Companies are investing heavily in proprietary AI platforms, advanced analytics tools, and integrated drug discovery ecosystems. Collaborative agreements focused on target identification, biomarker discovery, and AI-assisted therapeutic development are becoming common across the industry. Mergers, acquisitions, licensing agreements, and joint research initiatives continue to shape the competitive landscape.

Market participants are also emphasizing explainable AI, regulatory compliance, data security, and model validation to improve industry acceptance and support future commercialization efforts. Organizations that successfully demonstrate the ability to accelerate CNS drug discovery while reducing development risks are expected to gain significant competitive advantages.

Conclusion

The global AI in CNS drug discovery market is positioned for substantial growth through 2031, supported by the increasing prevalence of neurological and psychiatric disorders, rising adoption of artificial intelligence technologies, expanding biomedical data availability, and growing demand for more efficient drug development processes. AI is enabling researchers to address longstanding challenges associated with CNS drug discovery by improving target identification, biomarker development, compound optimization, and clinical trial design. While challenges related to data quality, regulatory uncertainty, and implementation costs remain, continued technological innovation and industry collaboration are expected to drive long-term market expansion and accelerate the development of next-generation CNS therapies.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Overview
• 1.2 Key Findings
• 1.3 Market Snapshot
• 1.4 Executive Insights
• 1.5 Strategic Recommendations
• 1.6 Future Market Outlook

2. Disease & Epidemiology Analysis

• 2.1 Overview of Central Nervous System (CNS) Disorders
  • 2.1.1 Alzheimer's Disease
  • 2.1.2 Parkinson's Disease
  • 2.1.3 Major Depressive Disorder (MDD)
  • 2.1.4 Bipolar Disorder
  • 2.1.5 Schizophrenia
  • 2.1.6 Epilepsy
  • 2.1.7 Multiple Sclerosis
  • 2.1.8 Amyotrophic Lateral Sclerosis (ALS)
  • 2.1.9 Huntington's Disease
  • 2.1.10 Autism Spectrum Disorder (ASD)
• 2.2 Global Burden of CNS Disorders
• 2.3 Epidemiology by Indication
  • 2.3.1 Alzheimer's Disease Prevalence and Incidence
  • 2.3.2 Parkinson's Disease Patient Population
  • 2.3.3 Depression Patient Population
  • 2.3.4 Schizophrenia Patient Population
  • 2.3.5 Epilepsy Patient Population
  • 2.3.6 Multiple Sclerosis Patient Population
• 2.4 Disease Burden by Age Group
• 2.5 Disease Burden by Gender
• 2.6 Economic Burden of CNS Disorders
• 2.7 Unmet Needs in CNS Drug Development
• 2.8 Clinical Trial Failure Rates in CNS Therapeutics
• 2.9 Role of AI in Addressing CNS Drug Discovery Challenges

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
  • 3.2.1 Rising CNS Disease Burden
  • 3.2.2 High Attrition Rates in CNS Drug Development
  • 3.2.3 Increasing Adoption of AI-Based Drug Discovery Platforms
  • 3.2.4 Growth in Multi-Omics and Real-World Data Availability
  • 3.2.5 Rising Investment in Precision Neuroscience
• 3.3 Market Restraints
  • 3.3.1 Limited Availability of High-Quality CNS Datasets
  • 3.3.2 Regulatory Uncertainty Around AI Models
  • 3.3.3 Validation Challenges for AI-Generated Targets
  • 3.3.4 Data Privacy and Security Concerns
• 3.4 Market Opportunities
  • 3.4.1 AI-Driven Target Identification
  • 3.4.2 Biomarker Discovery Platforms
  • 3.4.3 Drug Repurposing Applications
  • 3.4.4 Generative AI for Molecule Design
  • 3.4.5 Digital Twin Technologies in CNS Research
• 3.5 Market Challenges
  • 3.5.1 Biological Complexity of CNS Disorders
  • 3.5.2 Explainability of AI Algorithms
  • 3.5.3 Integration of Multi-Modal Data Sources
• 3.6 Porter's Five Forces Analysis
• 3.7 PESTLE Analysis
• 3.8 Value Chain Analysis
• 3.9 AI Drug Discovery Ecosystem Analysis

4. Commercial & Market Access

• 4.1 Commercial Landscape Overview
• 4.2 CNS Drug Development Economics
  • 4.2.1 Research and Development Costs
  • 4.2.2 Clinical Trial Cost Optimization Through AI
  • 4.2.3 Productivity Gains from AI Integration
• 4.3 Strategic Partnerships and Licensing Models
• 4.4 Venture Capital and Private Equity Activity
• 4.5 Pharmaceutical-AI Collaboration Landscape
• 4.6 Commercialization Challenges
• 4.7 Stakeholder Analysis
  • 4.7.1 Pharmaceutical Companies
  • 4.7.2 Biotechnology Companies
  • 4.7.3 AI Technology Providers
  • 4.7.4 Academic Research Institutes
  • 4.7.5 Regulatory Authorities

5. Innovation & Pipeline Landscape

• 5.1 Innovation Landscape Overview
• 5.2 AI Technologies Used in CNS Drug Discovery
  • 5.2.1 Machine Learning Platforms
  • 5.2.2 Deep Learning Models
  • 5.2.3 Generative AI Platforms
  • 5.2.4 Graph Neural Networks
  • 5.2.5 Natural Language Processing Applications
  • 5.2.6 Knowledge Graph-Based Discovery Platforms
• 5.3 CNS Drug Discovery Pipeline by Development Stage
  • 5.3.1 Discovery Stage Programs
  • 5.3.2 Preclinical Stage Programs
  • 5.3.3 Phase I Clinical Programs
  • 5.3.4 Phase II Clinical Programs
  • 5.3.5 Phase III Clinical Programs
• 5.4 Pipeline Analysis by Indication
  • 5.4.1 Alzheimer's Disease
  • 5.4.2 Parkinson's Disease
  • 5.4.3 Major Depressive Disorder
  • 5.4.4 Schizophrenia
  • 5.4.5 Epilepsy
  • 5.4.6 Multiple Sclerosis
  • 5.4.7 ALS
  • 5.4.8 Other CNS Disorders
• 5.5 Pipeline Analysis by Mechanism of Action
  • 5.5.1 Amyloid Beta Targeting Therapies
  • 5.5.2 Tau Protein Modulators
  • 5.5.3 Neuroinflammation Modulators
  • 5.5.4 Synaptic Plasticity Regulators
  • 5.5.5 Neuroprotective Agents
  • 5.5.6 Dopaminergic Pathway Modulators
• 5.6 Pipeline Analysis by Modality
  • 5.6.1 Small Molecules
  • 5.6.2 Biologics
  • 5.6.3 Gene Therapies
  • 5.6.4 RNA-Based Therapeutics
  • 5.6.5 Cell Therapies
• 5.7 Patent Landscape Analysis
• 5.8 Clinical Trial Landscape
• 5.9 Strategic Collaborations and Licensing Agreements
• 5.10 Funding and Investment Trends

6. Treatment Landscape

• 6.1 Current CNS Treatment Paradigm
• 6.2 Approved Therapies by Indication
  • 6.2.1 Alzheimer's Disease Treatments
  • 6.2.2 Parkinson's Disease Treatments
  • 6.2.3 Depression Treatments
  • 6.2.4 Schizophrenia Treatments
  • 6.2.5 Epilepsy Treatments
  • 6.2.6 Multiple Sclerosis Treatments
• 6.3 Challenges in Conventional CNS Drug Discovery
• 6.4 AI-Enabled Drug Discovery Workflow
• 6.5 Comparative Analysis: Traditional vs AI-Driven Drug Discovery
• 6.6 Precision Medicine and CNS Therapeutics
• 6.7 Future Treatment Development Models

7. Market Size & Forecast

• 7.1 Global Market Overview
• 7.2 Historical Market Analysis (2021-2025)
• 7.3 Market Forecast (2026-2033)
• 7.4 Forecast by Technology Type
• 7.5 Forecast by Application
• 7.6 Forecast by End User
• 7.7 Forecast by Drug Modality
• 7.8 Market Attractiveness Analysis

8. Market Segmentation

• 8.1 By Technology Type
  • 8.1.1 Machine Learning
  • 8.1.2 Deep Learning
  • 8.1.3 Generative AI
  • 8.1.4 Natural Language Processing
  • 8.1.5 Knowledge Graphs
  • 8.1.6 Computer Vision
• 8.2 By Indication
  • 8.2.1 Alzheimer's Disease
  • 8.2.2 Parkinson's Disease
  • 8.2.3 Major Depressive Disorder
  • 8.2.4 Schizophrenia
  • 8.2.5 Epilepsy
  • 8.2.6 Multiple Sclerosis
  • 8.2.7 ALS
  • 8.2.8 Other CNS Disorders
• 8.3 By End User
  • 8.3.1 Pharmaceutical Companies
  • 8.3.2 Biotechnology Companies
  • 8.3.3 Contract Research Organizations (CROs)
  • 8.3.4 Academic and Research Institutes

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Market Size and Growth Analysis
  • 9.1.2 Demand Drivers
  • 9.1.3 Regional Regulatory Overview
  • 9.1.4 Competitive Intensity Analysis
• 9.2 Europe
  • 9.2.1 Market Size and Growth Analysis
  • 9.2.2 Demand Drivers
  • 9.2.3 Regional Regulatory Overview
  • 9.2.4 Competitive Intensity Analysis
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Growth Analysis
  • 9.3.2 Demand Drivers
  • 9.3.3 Regional Regulatory Overview
  • 9.3.4 Competitive Intensity Analysis
• 9.4 Latin America
  • 9.4.1 Market Size and Growth Analysis
  • 9.4.2 Demand Drivers
  • 9.4.3 Regional Regulatory Overview
  • 9.4.4 Competitive Intensity Analysis
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Growth Analysis
  • 9.5.2 Demand Drivers
  • 9.5.3 Regional Regulatory Overview
  • 9.5.4 Competitive Intensity Analysis

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Global Regulatory Overview
• 11.2 United States Regulatory Framework (FDA)
  • 11.2.1 AI in Drug Development Guidance
  • 11.2.2 Drug Discovery and Clinical Development Regulations
  • 11.2.3 Data Integrity and Validation Requirements
• 11.3 Europe Regulatory Framework (EMA)
  • 11.3.1 AI Act and Healthcare Implications
  • 11.3.2 Drug Development Regulations
  • 11.3.3 Data Governance Requirements
• 11.4 Japan Regulatory Framework (PMDA)
  • 11.4.1 AI-Enabled Drug Development Policies
  • 11.4.2 Clinical Development Requirements
• 11.5 India Regulatory Framework (CDSCO)
  • 11.5.1 Drug Development Regulations
  • 11.5.2 Digital Health and AI Policies
• 11.6 China Regulatory Framework (NMPA)
  • 11.6.1 AI and Pharmaceutical Innovation Policies
  • 11.6.2 Clinical Development Requirements
• 11.7 Data Privacy and AI Governance Regulations
• 11.8 Intellectual Property and Patent Frameworks
• 11.9 Future Regulatory Trends for AI Drug Discovery

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Strategic Positioning Analysis
• 12.4 Pharmaceutical-AI Partnerships
• 12.5 Mergers and Acquisitions
• 12.6 Licensing and Co-Development Agreements
• 12.7 Funding and Investment Analysis
• 12.8 Competitive Dashboard

13. Company Profiles

• 13.1 Recursion Pharmaceuticals
• 13.2 Insilico Medicine
• 13.3 Exscientia plc
• 13.4 BenevolentAI
• 13.5 Schrodinger, Inc.
• 13.6 Relay Therapeutics
• 13.7 Neumora Therapeutics
• 13.8 Evotec SE
• 13.9 NVIDIA Corporation
• 13.10 Alphabet Inc.

14. Future Outlook

• 14.1 Future Evolution of AI in CNS Drug Discovery
• 14.2 Generative AI and Foundation Models in Drug Development
• 14.3 AI-Driven Precision Neuroscience
• 14.4 Digital Biomarkers and Multi-Omics Integration
• 14.5 AI-Enabled Clinical Trial Optimization
• 14.6 Future Partnership Models Between Pharma and AI Companies
• 14.7 Long-Term Growth Opportunities Through 2033

15. Methodology

• 15.1 Research Methodology Overview
• 15.2 Primary Research Framework
• 15.3 Secondary Research Framework
• 15.4 Epidemiology Data Collection Methodology
• 15.5 Pipeline Validation Methodology
• 15.6 Clinical Trial Verification Approach
• 15.7 Market Size Estimation Methodology
• 15.8 Forecasting Approach
• 15.9 Data Validation and Triangulation
• 15.10 Assumptions and Limitations